US EditionFDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer - AstraZeneca (NASDAQ:AZN)
UNITED STATES, JUN 24 – Datroway achieved a 45% objective response rate and 6.5 months median duration of response in EGFR-mutated NSCLC after prior EGFR-targeted and chemotherapy treatments, FDA said.
8 Articles
8 Articles
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer
AstraZeneca paid Japan’s Daiichi Sankyo a whopping $1 billion upfront back in 2020, and tacked on a potential $5 billion in milestone payments, for the chance to co-develop the antibody-drug conjugate DS-1062 outside of Japan. On Tuesday, the treatment, marketed as Datroway, was given the greenlight by the US Food and Drug Administration to treat a specific lung cancer, making it the first therapy of its kind to be approved for treating the dise…
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer - AstraZeneca (NASDAQ:AZN)
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
US approves AstraZeneca, Daiichi's treatment for lung cancer
(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this indication and expanding access for patients.
FDA Grants Accelerated Approval for DATROWAY in Advanced EGFR-Mutated Lung Cancer
WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have previously received EGFR-directed therapy and platinum-based chemotherapy. This milestone approval follows Priority Review and Breakthrough Therapy Designation and is based on promisi…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
